CH4

Optimal result: 0 – 10 ppm

Elevated levels of methane are indicative of IMO.

IMO, or intestinal methanogenic overgrowth, is an overgrowth of methane-producing archaea in the small and large intestines. Methanogens are not bacteria (the “B” in SIBO) but are archaea and may also overgrow in the colon and not just the small intestine (the “SI'' in SIBO).  In humans, excess methane production appears to be caused by Methanobrevibacter smithii, which is the predominant methanogen in the human gut.

A peak methane level > 10 ppm at any point is indicative of a methane-positive result.

Methane gas itself may slow intestinal transit, and patients with CH4-predominant bacterial overgrowth have been found to be five times more likely to have constipation compared to individuals with H2 - predominant overgrowth. Moreover, the severity of constipation has been found to directly correlate with the CH4 level.

- The peer-reviewed literature suggests an association with certain clinical conditions and methanogen overgrowth at levels as low as 3 ppm, CH4 values between 3 and 9 may indicate the need for clinical intervention in the symptomatic patient.

- ELEVATED BASELINE - An elevated baseline may be a more common pattern with CH4 positive tests primarily due to the ability of methanogenic organisms to ferment in the absence of an ingested carbohydrate substrate.

-------------------

It may be useful to discuss your results with a healthcare practitioner who is familiar with the management of intestinal methanogen overgrowth, such as a gastroenterologist or registered dietitian. If you undergo treatment for methane, it is easy to repeat the Methane Breath CH4ECK regularly to see if your methane has been reduced/eradicated.

-------------------

Methane (CH4) positivity on breath test has been associated with constipation. Patients with CH4-predominant bacterial overgrowth usually present with bloating and abdominal distention. However, they are 5 times more likely to have constipation as opposed to H2-predominant overgrowth. Moreover, the severity of constipation directly correlated with the methane level and the choice of antibiotics for the treatment of SIBO differs between these two groups as the predominant methanogen in the human gut, Methanobrevibacter smithii, is resistant to many antibiotics.

Conditions in which a high prevalence of overgrowth are commonly observed include, but are not limited to:

- Functional GI disorders (such as irritable bowel syndrome and gastroparesis)

- Hypothyroidism

- Neuromuscular diseases (such as restless leg syndrome)

- Inflammatory bowel disease (IBD)

- Pancreatic disease

- Celiac disease

- Liver disease

- Diabetes

- Fibromyalgia

- Rosacea

- Parkinson’s disease

- Obesity

- Interstitial cystitis

Treatment considerations:

Antibiotics are commonly used to treat SIBO, and studies show normalized breath tests as well as symptomatic relief. The underlying causes of SIBO must be treated properly. Otherwise, the likelihood of SIBO recurrence is very high, even after antibiotic therapy. 

In general, clinical management of the SIBO patient involves antibiotics and/or natural antimicrobial agents, promotility/prokinetic agents, nutrient supplementation for depleted nutrients and/ or for brush border healing, dietary interventions, meal spacing, and treatment of comorbid conditions.

Antibiotics

- Rifaximin is a non-absorbable antibiotic that has been FDA-approved for IBS-D, traveler’s diarrhea, and hepatic encephalopathy. It has been extensively studied in functional bowel disorders.8 It is efficacious against Grampositive and Gram-negative aerobic and anaerobic bacteria.4 It can target common SIBO organisms including E. coli, Klebsiella spp., Enterobacter spp., and E. faecalis. In addition to its direct antibiotic effects, rifaximin may also modulate the host inflammatory response with its anti-inflammatory effect. It is best used for hydrogenpredominant SIBO.

- While rifaximin can be used as an individual agent in patients with methane positive breath-testing, an additional agent may be a more effective treatment in instances of constipation-predominant symptomology or when both H2 and CH4 are present. Rifaximin plus neomycin, both non-absorbable antibiotics, have been described as an effective treatment for constipation-predominant cases. 

- A variety of other antibiotics have been studied for SIBO with varying efficacy. These include metronidazole, ciprofloxacin, norfloxacin, amoxicillin-clavulanic acid, cefoxitin, and doxycycline.

Natural Agents

In addition to pharmaceutical agents, limited evidence suggests a possible role for natural anti-microbial agents such as berberine, allicin (a component of garlic), oregano oil, and/or neem. One study showed that herbal therapies are at least as effective as rifaximin for SIBO resolution confirmed by lactulose breath test. The herbal products used in this study were a combination of Dysbiocide and FC Cidal (Biotics Research Laboratories) or Candibactin-AR and Candibactin-BR (Metagenics, Inc.). 

Elemental Diet

Elemental formulas are medical foods that provide nutrition that is absorbed in the proximal small intestine, thus limiting the delivery to the bacteria residing in the distal small intestine.

This diet may be an alternative to antibiotics in patients with allergies to antibiotics or who cannot tolerate antibiotics.

Provide Nutritional Support

Numerous nutritional consequences have been associated with SIBO including: weight loss, fat soluble vitamin deficiency, vitamin B12 deficiency, iron deficiency, hypoproteinemia, and low serum bile acids. Any patient with such secondary consequences may warrant nutraceutical support until SIBO has been addressed. Dietary adjustments to support the management of bacterial overgrowth are also commonly utilized in SIBO.

Because no dietary approach has been found to be uniformly effective for the management of symptoms, ongoing dietary modifications, based on patient feedback, is imperative. Common dietary SIBO interventions include the Specific Carbohydrate Diet (SCD), Low FODMAPs, SIBO Specific Diet (a combination of low FODMAPs and SCD designed by Allison Siebecker, ND), SIBO Bi-Phasic Diet (designed by Australian clinician Nirala Jacobi, ND), a liquid elemental diet, GAPS Diet, the Cedars-Sinai Medical Center’s Low Fermentation/SIBO Diet (Mark Pimentel, MD), and the Fast Tract Diet (designed by Norman Robillard, PhD).

Probiotics may be beneficial, but further studies are needed to determine the dose and strain. Prebiotics, often added to probiotic supplements, are fermentable foods for bacteria and can encourage overgrowth; these should be avoided during treatment.

Other supplements used by functional medicine key opinion leaders include hydrochloric acid, digestive enzymes, and brush border healing supplements, including mucilaginous herbs (licorice, slippery elm, aloe vera, marshmallow), colostrum, L-glutamine, zinc carnosine, vitamins A and D, curcumin, resveratrol, glutathione, and N-acetylcysteine. 

Correct the Underlying Cause

While it may not always be possible, depending on the condition, treatment should include strategies to minimize any risk factors or comorbid conditions for SIBO. Patients with impaired GI motility that affects the migrating motor complex (MMC), or anatomical abnormalities of the digestive tract, are particularly susceptible to SIBO.

Optimal functioning of the MMC may be supported in the following ways:

- Meal spacing every 4 – 5 hours and an overnight fast. The MMC is active during fasting states and is stopped by feedings.

- Use of prokinetic/promotility agents:

    » Pharmaceutical agents include low-dose erythromycin, low-dose naltrexone (LDN), and others. Erythromycin is a motilin agonist and can increase the frequency of phase III of the MMC. LDN is an opioid antagonist and can stimulate peristalsis and increase transit.

    » Natural agents include the botanical product Iberogast, ginger, and others. Iberogast consists of 9 herbs and, when compared with the prokinetics metoclopramide and cisapride, there was comparable effectiveness in the treatment of dyspepsia. Ginger increases motility during phase III of the MMC. 

Retesting

In a patient treated for SIBO, many variables affect the decision of when to retest, including the patient’s underlying condition and its severity, and the length and type of treatment. The North American consensus group suggests that breath tests may be performed shortly after cessation of antibiotic therapy to confirm eradication.

Utilization of breath methane levels for SIBO assessment is controversial largely due to a lack of validation related to diagnostic specifics such as timing and magnitude of increase; however, CH4 measurements are increasingly obtained to address other clinical questions. Recent evidence has associated CH4 production with the pathogenesis of common clinical conditions, such as obesity, irritable bowel syndrome (IBS), and constipation.

Methane is produced when archaea (single-celled organisms similar to bacteria) consume hydrogen.

Methane levels are considered abnormal if they reach ≥10 ppm (parts per million) at any point during the breath test.

Utilization of breath methane levels for SIBO assessment is controversial largely due to a lack of validation related to diagnostic specifics such as timing and magnitude of increase; however, CH4 measurements are increasingly obtained to address other clinical questions. Recent evidence has associated CH4 production with the pathogenesis of common clinical conditions, such as obesity, irritable bowel syndrome (IBS), and constipation.

- The peer-reviewed literature suggests an association with certain clinical conditions and methanogen overgrowth at levels as low as 3 ppm, CH4 values between 3 and 9 may indicate the need for clinical intervention in the symptomatic patient.

- ELEVATED BASELINE - An elevated baseline may be a more common pattern with CH4 positive tests primarily due to the ability of methanogenic organisms to ferment in the absence of an ingested carbohydrate substrate.

Methane gas itself may slow intestinal transit, and patients with CH4-predominant bacterial overgrowth have been found to be five times more likely to have constipation compared to individuals with H2 - predominant overgrowth. Moreover, the severity of constipation has been found to directly correlate with the CH4 level.

Risk factors:

Decreased intestinal motility is a key factor in the development of SIBO and its recurrence. Out of all the diseases and disorders associated with SIBO, 90% of cases involve either small intestinal motility disorders and/or chronic pancreatitis.

The migrating motor complex (MMC) describes the waves of electromechanical activity that sweep through the intestines in regular cycles between meals. The MMC triggers waves that move non-digestible substances through the gastrointestinal tract from the stomach distally to the terminal ileum. In addition, the MMC is responsible for moving bacteria from the small intestine to the large intestine, as well as inhibiting the migration of colonic bacteria into the terminal ileum. Any disorder that impairs MMC function can be a risk factor for SIBO. Gastroenteritis that leads to post-infectious IBS-D is thought to be a risk factor for SIBO. Campylobacter jejuni, Salmonella, E. coli, and Shigella produce cytolethal distending toxin (CDT), and the host can produce an autoimmune response that damages the pacemaker cells for the MMC, resulting in decreased MMC activity. Other key SIBO risk factors include conditions that result in immunocompromise, decreased bacteriostatic digestive secretions (HCl, pancreatic enzymes, bile acids), and ileocecal valve dysfunction.

Complications of SIBO:

Because SIBO is not consistently characterized by the same species, different symptoms or complications may result, depending on the organisms that are present and their specific function in the GI tract. SIBO can result in damage to the small intestinal mucosa leading to malabsorption and intestinal permeability. Microscopic inflammatory changes in the lamina propria and villous atrophy are common. Destruction of the intestinal mucosa can result in reduced disaccharidase function and increased intraluminal bacterial carbohydrate degradation, causing SIBO symptoms. The bacteria themselves can consume nutrients, leading to micronutrient deficiencies, and deconjugate bile acids, leading to fat and fat-soluble vitamin malabsorption. Bacteria can produce toxic substances resulting in increased serum endotoxin, stimulating inflammatory cytokine production. 

SIBO complications include:

- Weight loss

- Steatorrhea

- Vitamin/mineral deficiency

    » Fat-soluble vitamins (A,D,E,K)

    » Vitamin B12

    » Iron

- Hypoproteinemia/hypoalbuminemia

- Bile acid deficiency

- Anemia

- Osteoporosis

- Neuropathies

------------------

References:

Rezaie A, Buresi M, Lembo A, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. The American journal of gastroenterology. May 2017;112(5):775-784. [PubMed]

Chatterjee S, Park S, Low K et al. The degree of breath methane production in IBS correlates with the severity of constipation. Am J Gastroenterol 2007;102:837–841. [PubMed]

Attaluri A, Jackson M, Valestin J et al. Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol 2010;105:1407–1411. [PubMed]

Hwang L, Low K, Khoshini R et al. Evaluating breath methane as a diagnostic test for constipation-predominant IBS. Dig Dis Sci 2010;55:398–403. [PubMed]

Kunkel D, Basseri RJ, Makhani MD et al. Methane on breath testing is associated with constipation: a systematic review and meta-analysis. Dig Dis Sci 2011;56:1612–1618. [PubMed]

Low K, Hwang L, Hua J et al. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol 2010;44:547–550. [PubMed]

Pimentel M, Chang C, Chua KS et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci 2014;59:1278–1285. [PubMed]

Rezaie A, Pimentel M, Rao SS. How to test and treat small intestinal bacterial overgrowth: an evidence-based approach. Curr Gastroenterol Rep 2016;18:8. [PubMed]

CH4
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond CH4 — 10,000+ markers explained
One CH4 result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

Article Review Log
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro